Literature DB >> 27769987

Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis.

Kensuke Yamamura1, Yoshifumi Baba1, Shigeki Nakagawa1, Kosuke Mima1, Keisuke Miyake1, Kenichi Nakamura1, Hiroshi Sawayama1, Koichi Kinoshita1, Takatsugu Ishimoto1, Masaaki Iwatsuki1, Yasuo Sakamoto1, Yoichi Yamashita1, Naoya Yoshida1, Masayuki Watanabe2, Hideo Baba3.   

Abstract

PURPOSE: Fusobacterium nucleatum (F. nucleatum) is a component of the human microbiome that primarily inhabits the oral cavity. It causes periodontal disease and has also been implicated in the development of human cancers. Although there are several reports of the relationship between F. nucleatum and the clinical outcome in human cancers, its prognostic significance in esophageal cancer remains unclear. EXPERIMENTAL
DESIGN: We quantified F. nucleatum DNA in 325 resected esophageal cancer specimens by qPCR. Significant pathways in F. nucleatum-positive esophageal cancer tissues were identified by Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using microarray data.
RESULTS: Esophageal cancer tissues contained significantly more F. nucleatum DNA than matched normal esophageal mucosa (P = 0.021; n = 60). F. nucleatum DNA was detected in 74 of 325 cases (23%). F. nucleatum DNA positivity was significantly associated with tumor stage, but not with sex, age, performance status, tobacco use, alcohol use, histology, tumor location, or preoperative treatment. F. nucleatum DNA positivity was also significantly associated with cancer-specific survival [log-rank P = 0.0039; univariate HR = 2.01; 95% confidence interval (CI), 1.22-3.23; P = 0.0068; multivariate HR = 1.78; 95% CI, 1.06-2.94; P = 0.031]. The top-ranked KEGG pathway in F. nucleatum-positive tissues was "cytokine-cytokine receptor interaction." A significant relationship between F. nucleatum and the chemokine CCL20 was validated by IHC.
CONCLUSIONS: F. nucleatum in esophageal cancer tissues was associated with shorter survival, suggesting a potential role as a prognostic biomarker. F. nucleatum might also contribute to aggressive tumor behavior through activation of chemokines, such as CCL20. Clin Cancer Res; 22(22); 5574-81. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27769987     DOI: 10.1158/1078-0432.CCR-16-1786

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  104 in total

1.  Mucosal cancer-associated microbes and anastomotic leakage after resection of colorectal carcinoma.

Authors:  Kosuke Mima; Yuki Sakamoto; Keisuke Kosumi; Yoko Ogata; Keisuke Miyake; Yukiharu Hiyoshi; Takatsugu Ishimoto; Masaaki Iwatsuki; Yoshifumi Baba; Shiro Iwagami; Yuji Miyamoto; Naoya Yoshida; Shuji Ogino; Hideo Baba
Journal:  Surg Oncol       Date:  2019-11-18       Impact factor: 3.279

2.  High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.

Authors:  Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Petri Lehenkari; Juha Saarnio; Tuomo J Karttunen
Journal:  Virchows Arch       Date:  2017-02-12       Impact factor: 4.064

3.  Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk region of China.

Authors:  Dantong Shao; Emily Vogtmann; Anqi Liu; Junjie Qin; Wen Chen; Christian C Abnet; Wenqiang Wei
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

4.  Gene-expression signature may be useful for the prediction of lymph node metastasis in esophageal cancer.

Authors:  Yoshifumi Baba; Hideo Baba
Journal:  Ann Transl Med       Date:  2018-06

5.  Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.

Authors:  Kensuke Yamamura; Daisuke Izumi; Raju Kandimalla; Fuminori Sonohara; Yoshifumi Baba; Naoya Yoshida; Yasuhiro Kodera; Hideo Baba; Ajay Goel
Journal:  Clin Cancer Res       Date:  2019-07-29       Impact factor: 12.531

6.  Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus.

Authors:  Dai Shimizu; Masahiko Koike; Mitsuro Kanda; Fuminori Sonohara; Norifumi Hattori; Masamichi Hayashi; Chie Tanaka; Suguru Yamada; Yasuhiro Kodera
Journal:  Surg Today       Date:  2020-07-07       Impact factor: 2.549

7.  Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status.

Authors:  Ji Ae Lee; Seung-Yeon Yoo; Hyeon Jeong Oh; Seorin Jeong; Nam-Yun Cho; Gyeong Hoon Kang; Jung Ho Kim
Journal:  Cancer Immunol Immunother       Date:  2020-07-04       Impact factor: 6.968

8.  Preoperative iron status is a prognosis factor for stage II and III colorectal cancer.

Authors:  Hiroshi Sawayama; Yuji Miyamoto; Kosuke Mima; Rikako Kato; Katsuhiro Ogawa; Yukiharu Hiyoshi; Mototsugu Shimokawa; Takahiko Akiyama; Yuki Kiyozumi; Shiro Iwagami; Masaaki Iwatsuki; Yoshifumi Baba; Naoya Yoshida; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2021-07-23       Impact factor: 3.402

Review 9.  The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.

Authors:  Kosuke Mima; Shuji Ogino; Shigeki Nakagawa; Hiroshi Sawayama; Koichi Kinoshita; Ryuichi Krashima; Takatsugu Ishimoto; Katsunori Imai; Masaaki Iwatsuki; Daisuke Hashimoto; Yoshifumi Baba; Yasuo Sakamoto; Yo-Ichi Yamashita; Naoya Yoshida; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  Surg Oncol       Date:  2017-07-21       Impact factor: 3.279

10.  Fusobacterium nucleatum is associated with worse prognosis in Lauren's diffuse type gastric cancer patients.

Authors:  Ellen Teresa Boehm; Cosima Thon; Juozas Kupcinskas; Ruta Steponaitiene; Jurgita Skieceviciene; Ali Canbay; Peter Malfertheiner; Alexander Link
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.